Osimertinib as first-line treatment in EGFR-mutated non-small-cell lung cancer
File(s)nejme1714580.pdf (107.71 KB)
Published version
Author(s)
Popat, Sanjay
Type
Journal Article
Date Issued
2018-01-11
Date Acceptance
2018-01-01
Citation
New England Journal of Medicine, 2018, 378 (2), pp.192-193
ISSN
0028-4793
Publisher
Massachusetts Medical Society
Start Page
192
End Page
193
Journal / Book Title
New England Journal of Medicine
Volume
378
Issue
2
Copyright Statement
From The New England Journal of Medicine. Copyright © 2018 Massachusetts Medical Society. Reprinted with permission.
Subjects
Science & Technology
Life Sciences & Biomedicine
Medicine, General & Internal
General & Internal Medicine
OPEN-LABEL
TRIAL
CHEMOTHERAPY
GEFITINIB
AFATINIB
Publication Status
Published